Latest Pharma and Biotech News
Generics
24 July 2025 Hospitals are rationing cancer treatments. Pharmacies are scrambling to fill routine antibiotic prescriptions. And across the USA, patients are facing growing delays, substitutions, or outright denials of essential medicines, not because the drugs don’t exist, but because the supply chains behind them have buckled.
Today's issue
Refine Search
Biotechnology
French drugmaker Ipsen announced that the European Commission (EC) has approved Cabometyx (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. 25 July 2025
Biotechnology
It has been a stellar week for Abivax, a French biotech developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. 25 July 2025
Pharmaceutical
The Trump administration has asked the US Supreme Court to allow the National Institutes of Health (NIH) to resume canceling hundreds of research grants supporting work on health equity, racial disparities, and other diversity-related public health initiatives. 25 July 2025
Biotechnology
In an import contrast to events in the USA, UK pharma major GSK late Thursday announced the approval of Blenrep (belantamab mafodotin) by the European Commission. 25 July 2025
Biotechnology
Following the positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on June 19, 2025, the European Commission has approved French pharma major Sanofi's (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the induction treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who are eligible for autologous stem cell transplant. 25 July 2025
Pharmaceutical
Swiss pharma major Novartis has entered into an exclusive option and license deal with Matchpoint Therapeutics to develop oral covalent inhibitors for inflammatory diseases, the companies said on July 24. The privately held biotech could receive as much as $1 billion in total payments if milestones are met. 25 July 2025
Generics
Hospitals are rationing cancer treatments. Pharmacies are scrambling to fill routine antibiotic prescriptions. And across the USA, patients are facing growing delays, substitutions, or outright denials of essential medicines, not because the drugs don’t exist, but because the supply chains behind them have buckled. 24 July 2025
Biotechnology
Italian family-owned drugmaker Chiesi Farmaceutici and Switzerland’s Serna Bio today announced a global drug discovery and collaboration agreement to discover and develop novel small molecule drugs that target RNA against an undisclosed ‘hard-to-drug’ target of interest for respiratory diseases. 24 July 2025
Biotechnology
Australian venture capital firm Brandon Capital has closed its largest fund to date, raising A$439 million ($296 million) for its sixth life sciences fund. The final close brings in new government support, signaling increasing national focus on growing the domestic biotech sector. 24 July 2025
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved US pharma major AbbVie’s Elahere (mirvetuximab soravtansine) to treat adults with ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. 24 July 2025
Biotechnology
California’s Gate Bioscience, a biotech developing molecular gates, a new class of small molecule drugs to eliminate disease-causing proteins at their source, has announced a collaboration and license agreement with US pharma major Eli Lilly. 24 July 2025
Pharmaceutical
Privately-held Danish dermatology specialist LEO Pharma today revealed that the US Food and Drug Administration (FDA) has approved Anzupgo (delgocitinib) cream (20 mg/g) for the topical treatment of moderate-to-severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. 24 July 2025
Biotechnology
Swiss pharma giant Roche has paused shipments of the gene therapy Elevidys (delandistrogene moxeparvovec) for new orders in certain countries outside the USA. 24 July 2025
Biotechnology
China’s Alebund Pharmaceuticals announced positive top-line Phase III results highlighting that the use of AP301 demonstrated a statistically-significant and clinically-meaningful improvement in serum phosphorus control in dialysis patients with hyperphosphatemia (HP). 24 July 2025
Biotechnology
US biotech Avidity Biosciences’ stock rose 4% on Wednesday after the company announced that the US Food and Drug Administration (FDA) had granted Breakthrough Therapy designation to delpacibart zotadirsen (del-zota, formerly known as AOC 1044), the company’s investigational therapy for the treatment of people with Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44). 24 July 2025
Biotechnology
UK pharma major AstraZeneca is preparing to advance gefurulimab as a potential new treatment for generalized myasthenia gravis, following positive results in a global Phase III trial that could pave the way for regulatory filings. 24 July 2025
Biotechnology
The US Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) for GSK’s Blenrep (belantamab mafodotin-blmf) combinations for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. 24 July 2025
Pharmaceutical
The number of new pharmaceutical companies being set up in Russia is steadily declining due to sanctions and the ever-growing isolation of the country in the international arena, reports The Pharma Letter’s local correspondent. 24 July 2025
Pharmaceutical
China remains the most popular country for clinical trials outside North America and Europe in the second quarter (Q2) of 2025, according to a report by the data and analytics company GlobalData. 24 July 2025
Pharmaceutical
Swiss pharma giant Roche this morning released financial results for the first half of 2025, showing that sales grew 7% (+4% in Swiss francs) to 30.9 billion francs ($35.1 billion) due to strong demand for pharmaceutical products. Sales were in line with Visible Alpha consensus of 30.80 billion francs. 24 July 2025
All news
Biotechnology
French drugmaker Ipsen announced that the European Commission (EC) has approved Cabometyx (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. 25 July 2025
Biotechnology
It has been a stellar week for Abivax, a French biotech developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. 25 July 2025
Pharmaceutical
The Trump administration has asked the US Supreme Court to allow the National Institutes of Health (NIH) to resume canceling hundreds of research grants supporting work on health equity, racial disparities, and other diversity-related public health initiatives. 25 July 2025
Biotechnology
In an import contrast to events in the USA, UK pharma major GSK late Thursday announced the approval of Blenrep (belantamab mafodotin) by the European Commission. 25 July 2025
Biotechnology
Following the positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on June 19, 2025, the European Commission has approved French pharma major Sanofi's (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the induction treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who are eligible for autologous stem cell transplant. 25 July 2025
Pharmaceutical
Swiss pharma major Novartis has entered into an exclusive option and license deal with Matchpoint Therapeutics to develop oral covalent inhibitors for inflammatory diseases, the companies said on July 24. The privately held biotech could receive as much as $1 billion in total payments if milestones are met. 25 July 2025
Generics
Hospitals are rationing cancer treatments. Pharmacies are scrambling to fill routine antibiotic prescriptions. And across the USA, patients are facing growing delays, substitutions, or outright denials of essential medicines, not because the drugs don’t exist, but because the supply chains behind them have buckled. 24 July 2025
Biotechnology
Italian family-owned drugmaker Chiesi Farmaceutici and Switzerland’s Serna Bio today announced a global drug discovery and collaboration agreement to discover and develop novel small molecule drugs that target RNA against an undisclosed ‘hard-to-drug’ target of interest for respiratory diseases. 24 July 2025
Biotechnology
Australian venture capital firm Brandon Capital has closed its largest fund to date, raising A$439 million ($296 million) for its sixth life sciences fund. The final close brings in new government support, signaling increasing national focus on growing the domestic biotech sector. 24 July 2025
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved US pharma major AbbVie’s Elahere (mirvetuximab soravtansine) to treat adults with ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. 24 July 2025
Biotechnology
California’s Gate Bioscience, a biotech developing molecular gates, a new class of small molecule drugs to eliminate disease-causing proteins at their source, has announced a collaboration and license agreement with US pharma major Eli Lilly. 24 July 2025
Pharmaceutical
Privately-held Danish dermatology specialist LEO Pharma today revealed that the US Food and Drug Administration (FDA) has approved Anzupgo (delgocitinib) cream (20 mg/g) for the topical treatment of moderate-to-severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. 24 July 2025
Biotechnology
Swiss pharma giant Roche has paused shipments of the gene therapy Elevidys (delandistrogene moxeparvovec) for new orders in certain countries outside the USA. 24 July 2025
Biotechnology
China’s Alebund Pharmaceuticals announced positive top-line Phase III results highlighting that the use of AP301 demonstrated a statistically-significant and clinically-meaningful improvement in serum phosphorus control in dialysis patients with hyperphosphatemia (HP). 24 July 2025
Biotechnology
US biotech Avidity Biosciences’ stock rose 4% on Wednesday after the company announced that the US Food and Drug Administration (FDA) had granted Breakthrough Therapy designation to delpacibart zotadirsen (del-zota, formerly known as AOC 1044), the company’s investigational therapy for the treatment of people with Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44). 24 July 2025
Biotechnology
UK pharma major AstraZeneca is preparing to advance gefurulimab as a potential new treatment for generalized myasthenia gravis, following positive results in a global Phase III trial that could pave the way for regulatory filings. 24 July 2025
Biotechnology
The US Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) for GSK’s Blenrep (belantamab mafodotin-blmf) combinations for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. 24 July 2025
Pharmaceutical
The number of new pharmaceutical companies being set up in Russia is steadily declining due to sanctions and the ever-growing isolation of the country in the international arena, reports The Pharma Letter’s local correspondent. 24 July 2025
Pharmaceutical
China remains the most popular country for clinical trials outside North America and Europe in the second quarter (Q2) of 2025, according to a report by the data and analytics company GlobalData. 24 July 2025
Pharmaceutical
Swiss pharma giant Roche this morning released financial results for the first half of 2025, showing that sales grew 7% (+4% in Swiss francs) to 30.9 billion francs ($35.1 billion) due to strong demand for pharmaceutical products. Sales were in line with Visible Alpha consensus of 30.80 billion francs. 24 July 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze